RxDoctor Payments Data

Temidayo Adelekun, MD

Internal Medicine · Kings Mountain, NCNPI 1962497537

Payments from drug & device makers

$8,394in general payments, 2019–2025

Across 362 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$828
  • Johnson & Johnson$643
  • GSK$600
  • Pfizer$446
  • Amgen$443
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,29299%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,394 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$65,553
Medicare patients
137
Services billed
1,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol49$57,373
FanaptIloperidone24$56,491
JardianceEmpagliflozin41$47,116
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$44,046
EliquisApixaban40$40,842
RybelsusSemaglutide15$29,566
OzempicSemaglutide13$22,552
MounjaroTirzepatide15$21,931
MyrbetriqMirabegron22$15,183
MovantikNaloxegol Oxalate12$14,961
Combivent RespimatIpratropium/Albuterol Sulfate29$14,672
LinzessLinaclotide12$13,020
SymbicortBudesonide/Formoterol Fumarate28$9,176
Tresiba Flextouch U-200Insulin Degludec14$8,101
Albuterol Sulfate HfaAlbuterol Sulfate101$4,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$1,614$66,54977 claims
Boehringer IngelheimJardiance, Combivent Respimat$311$61,78870 claims
Vanda Pharmaceuticals Inc.Fanapt$27$56,49124 claims
Novo NordiskRybelsus, Ozempic$150$52,11828 claims
GSKTrelegy Ellipta$600$44,04636 claims
PfizerEliquis$446$40,84240 claims
Lilly USA, LLCMounjaro$163$21,93115 claims
Astellas Pharma US IncMyrbetriq$122$15,18322 claims
AbbVieLinzess$828$13,02012 claims
Scilex Pharmaceuticals Inc.Colchicine$28$1,26117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Kings Mountain

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →